FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

This is a first-in-human study testing the safety and early effectiveness of a new experimental drug called TUB-040 in people with two types of hard-to-treat cancers: platinum-resistant ovarian cancer, or non-small cell lung cancer (adenocarcinoma type) that has returned after treatment. TUB-040 is an antibody-drug conjugate — a targeted molecule that delivers a toxic payload directly to cancer cells. **You may be eligible if...** - You are 18 years or older - You have platinum-resistant ovarian cancer or relapsed/refractory lung adenocarcinoma - Your cancer can be measured on imaging and is not curable with available treatments - You are in good general health (ECOG score 0–1) - Your expected survival from the disease is more than 12 weeks - You have tumor tissue available for biomarker testing **You may NOT be eligible if...** - You still have standard treatments available that could benefit you - You have serious heart, kidney, liver, or lung conditions - You are pregnant or breastfeeding - You have had certain recent prior treatments that would interfere with this drug Talk to your doctor to see if this trial is right for you.